Clinical observation of metformin combined with pioglitazone in treating newly diagnosed obesity type 2 diabetes patients

Objective To investigate the therapeutic effect of metformin combined pioglitazone on the newly diagnosed obesity type 2 diabetes(T2DM).Methods 71 patients with newly diagnosed obesity type 2 diabetes were randomly divided into two groups.25 patients in treatment group were treated by metformin(500 mg twice daily) and pioglitazone(30 mg once daily).The control group involved metformin group and pioglitazone group,24 patients in metformin group were given metformin(500 mg twice daily),22 patients in pioglitazone group were given pioglitazone(30 mg once daily).The treatment lasted for 12 weeks.The change of fasting plasma glucose(FPG),2 hour postprandial plasma glucose(2hPG),HbA_(1C),fasting plasma insulin(FINS) and 2 hour postprandial plasma insulin(P2hINS) levels were determined.Results After the treatment,the level of FPG,2hPG,HbA_(1C),FINS and P2hINS decreased significantly in three groups.The results showed that metformin group and pioglitazone group had similar curative effect,the treatment group was better in decreasing level of insulin and improving glucose metabolism disturbance as compared with metformin group and pioglitazone group.Conclusion Metformin combined pioglitazone is one of the choices in the newly diagnosed obesity T2DM patients whose glycemia was poorly controlled with single medication.